These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22421426)

  • 41. Direct injection of liposome-encapsulated doxorubicin optimizes chemomyectomy in rabbit eyelid.
    McLoon LK; Wirtschafter JD
    Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2561-7. PubMed ID: 10509650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil).
    Tsukioka Y; Matsumura Y; Hamaguchi T; Koike H; Moriyasu F; Kakizoe T
    Jpn J Cancer Res; 2002 Oct; 93(10):1145-53. PubMed ID: 12417045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
    Rose PG
    Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reversible ageusia after chemotherapy with pegylated liposomal doxorubicin.
    Kiewe P; Jovanovic S; Thiel E; Korfel A
    Ann Pharmacother; 2004; 38(7-8):1212-4. PubMed ID: 15161947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
    Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization.
    Mészáros T; Kozma GT; Shimizu T; Miyahara K; Turjeman K; Ishida T; Barenholz Y; Urbanics R; Szebeni J
    Int J Nanomedicine; 2018; 13():6345-6357. PubMed ID: 30349254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
    Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
    Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hyperthermia and liposomal encapsulated doxorubicin.
    Ben-Yosef R; Gipps M; Zeira M
    Isr Med Assoc J; 2003 Jun; 5(6):407-9. PubMed ID: 12841010
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II study of liposomal doxorubicin in advanced gynecologic cancers.
    Israel VP; Garcia AA; Roman L; Muderspach L; Burnett A; Jeffers S; Muggia FM
    Gynecol Oncol; 2000 Aug; 78(2):143-7. PubMed ID: 10926793
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction.
    Szebeni J; Baranyi L; Savay S; Bodo M; Morse DS; Basta M; Stahl GL; Bünger R; Alving CR
    Am J Physiol Heart Circ Physiol; 2000 Sep; 279(3):H1319-28. PubMed ID: 10993799
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy.
    Dézsi L; Mészáros T; Őrfi E; Fülöp TG; Hennies M; Rosivall L; Hamar P; Szebeni J; Szénási G
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31505853
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
    Working PK; Newman MS; Sullivan T; Yarrington J
    J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Application of oligo-(14-amino-3,6,9,12-tetraoxatetradecanoic acid) lipid conjugates as steric barrier molecules in liposomal formulations.
    Ansell SM; Kojic LD; Hankins JS; Sekirov L; Boey A; Lee DK; Bennett AR; Klimuk SK; Harasym TO; Dos Santos N; Semple SC
    Bioconjug Chem; 1999; 10(4):653-66. PubMed ID: 10411464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action.
    Russell LM; Hultz M; Searson PC
    J Control Release; 2018 Jan; 269():171-176. PubMed ID: 29122661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
    Amantea MA; Forrest A; Northfelt DW; Mamelok R
    Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice.
    Őrfi E; Mészáros T; Hennies M; Fülöp T; Dézsi L; Nardocci A; Rosivall L; Hamar P; Neun BW; Dobrovolskaia MA; Szebeni J; Szénási G
    Int J Nanomedicine; 2019; 14():1563-1573. PubMed ID: 30880965
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
    Fujisaka Y; Horiike A; Shimizu T; Yamamoto N; Yamada Y; Tamura T
    Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.